АСОЦІАЦІЯ МІЖ ЕКСПРЕСІЄЮ ЛІПОПРОТЕЇНЛІПАЗИ ТА ПОЛІМОРФІЗМАМИ ГЕНА TP53 У ХВОРИХ НА ХРОНІЧНУ ЛІМФОЦИТАРНУ ЛЕЙКЕМІЮ

Summary. Background: Expression of lipoprotein lipase (LPL) correlates with unmutated (UM) status of the variable region of the heavy chain of immunoglobulin (IGHV) genes, but the expression level of LPL in UM chronic lymphocytic leukemia (CLL) cases varies significantly. Aim: To study the associati...

Повний опис

Збережено в:
Бібліографічні деталі
Дата:2023
Автори: Abramenko, I., Bilous, N., Chumak, A., Dyagil, I., Martina, Z.
Формат: Стаття
Мова:English
Опубліковано: PH Akademperiodyka 2023
Теми:
Онлайн доступ:https://exp-oncology.com.ua/index.php/Exp/article/view/2021-3-7
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
Назва журналу:Experimental Oncology

Репозитарії

Experimental Oncology
Опис
Резюме:Summary. Background: Expression of lipoprotein lipase (LPL) correlates with unmutated (UM) status of the variable region of the heavy chain of immunoglobulin (IGHV) genes, but the expression level of LPL in UM chronic lymphocytic leukemia (CLL) cases varies significantly. Aim: To study the association of LPL expression with the genetic variants of the TP53 gene since both genes are involved in lipid metabolism. Materials and Methods: Expression of LPL mRNA was measured in peripheral blood mononuclears of 45 CLL patients with UM IGHV genes by real-time quantitative reverse transcription polymerase chain reaction. Mutational status of IGHV genes and TP53 genotyping (rs1042522, rs1642785, rs17883323, rs2909430, rs145153611, rs113530090, rs12947788, rs12951053, and rs17878362) were performed by polymerase chain reaction amplification followed by direct sequencing. Results: Observed CLL patients were divided on groups with low (11.17 ± 2.66) and high (275.48 ± 39.37) LPL expression. In CLL patients with UM IGHV genes and low LPL expression we found an increased frequency of rs1042522 G (p = 0.0036), rs1642785 C (p = 0.0001), and rs17878362A2 alleles (p = 0.0091). The possible functional significance of these changes is discussed. Conclusion: Some polymorphic variants of TP53 may be genetic modifiers for LPL expression level in CLL leukemic B-cells. Further research is required in a larger cohort to confirm these findings.